MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
Galmed Pharmaceuticals Ltd. Operating Expenses 2011-2026 | GLMD
Annual Operating Expenses Galmed Pharmaceuticals Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 32.9 M | - | 22.4 M | 12.8 M | 13.4 M | 17.3 M | 10.9 M | 9.14 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.9 M | 9.14 M | 17 M |
Quarterly Operating Expenses Galmed Pharmaceuticals Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 8.41 M | - | - | - | 5.82 M | - | - | - | 4.7 M | - | - | - | 2.78 M | - | - | - | 2.7 M | - | - | - | 4.22 M | - | - | - | 2.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.41 M | 2.53 M | 4.45 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
512 M | $ 97.57 | 2.17 % | $ 27.2 B | Germany |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.49 | 6.25 % | $ 83.9 M |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.63 | -2.42 % | $ 8.73 B |  Australia |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Esperion Therapeutics
ESPR
|
343 M | $ 2.15 | -0.69 % | $ 447 M | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.83 | 2.5 % | $ 27.9 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 20.87 | 2.45 % | $ 976 M | USA |
 |
Genmab A/S
GMAB
|
67.9 M | $ 28.23 | -0.07 % | $ 18 B |  Danmark |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.24 | 0.3 % | $ 6.83 B |  Spain |
 |
GT Biopharma
GTBP
|
21.3 M | $ 0.37 | -0.92 % | $ 2.04 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
Halozyme Therapeutics
HALO
|
218 M | $ 66.86 | -1.42 % | $ 8.01 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Harmony Biosciences Holdings
HRMY
|
462 M | $ 28.5 | -1.35 % | $ 1.64 B | USA |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.43 | 2.14 % | $ 368 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.91 | -0.26 % | $ 4.79 M | Israel |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.18 | 2.45 % | $ 447 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.96 | -1.03 % | $ 3.05 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
58.1 M | $ 32.21 | -0.09 % | $ 2.14 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.49 | -0.34 % | $ 397 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Incyte Corporation
INCY
|
1.62 B | $ 94.65 | -1.48 % | $ 18.5 B | USA |
 |
Cidara Therapeutics
CDTX
|
177 M | - | - | $ 1.41 B | USA |
 |
Innate Pharma S.A.
IPHA
|
63 M | $ 1.48 | 4.61 % | $ 235 M | France |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
53.7 M | $ 2.57 | 0.78 % | $ 16.1 M | USA |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
Inventiva S.A.
IVA
|
36.2 M | $ 5.15 | -2.09 % | $ 138 M | France |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |